BIZARRE: 14 | Mind Blowing Facts

Benzinga's Top Ratings Upgrades, Downgrades For June 2, 2022

 

Benzinga · Jun 2, 2022

What's Going On With Chewy Stock Today?

Chewy Inc (NYSE: CHWY) shares are trading lower Wednesday after Piper Sandler cut its price target ahead of the company's earnings results.

Benzinga · Jun 1, 2022

9 Salesforce Analysts React To Q1 Earnings Beat: 'Next Quality Software GARP Stock'

Salesforce Inc (NYSE: CRM) shares jumped Wednesday morning after the company reported first-quarter earnings and raised its profit forecast.

Benzinga · Jun 1, 2022

Piper Sandler Lists What Could Go Right For Bill.Com

Piper Sandler analyst Brent Bracelin maintained Bill.Com Holdings, Inc (NYSE:BILL) with an Overweight and lowered the price target from $300 to $205 (92.4% upside). After six months of fielding investor questions, Piper Sandler published a new 'what could go right?' report series.  The report involved in-person meetings with senior leadership to understand better how different cloud business…

Benzinga · May 24, 2022

10 Biggest Price Target Changes For Tuesday

Needham reduced WalkMe Ltd. (NASDAQ: WKME) price target from $40 to $20. WalkMe shares dropped 8.1% to close at $12.20 on Monday.

Benzinga · May 24, 2022

Piper Sandler Maintains Neutral Rating for Marathon Petroleum: Here's What You Need To Know

Piper Sandler has decided to maintain its Neutral rating of Marathon Petroleum (NYSE:MPC) and raise its price target from $96.00 to $106.00. Shares of Marathon Petroleum are trading up 2.15% over the last 24 hours, at $98.64 per share.

Benzinga · May 23, 2022

Piper Sandler Maintains Overweight Rating for Altimmune: Here's What You Need To Know

Piper Sandler has decided to maintain its Overweight rating of Altimmune (NASDAQ:ALT) and lower its price target from $34.00 to $25.00. Shares of Altimmune are trading down 0.57% over the last 24 hours, at $5.26 per share. A move to $25.00 would account for a 375.29% increase from the current…

Benzinga · May 18, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2022

 

Benzinga · May 18, 2022

Piper Sandler Maintains Neutral Rating for Pacific Biosciences: Here's What You Need To Know

Piper Sandler has decided to maintain its Neutral rating of Pacific Biosciences (NASDAQ:PACB) and lower its price target from $13.00 to $6.00. Shares of Pacific Biosciences are trading down 2.74% over the last 24 hours, at $5.68 per share.

Benzinga · May 16, 2022

10 Biggest Price Target Changes For Thursday

Wells Fargo cut the price target on Ford Motor Company (NYSE: F) from $24 to $12. Ford shares fell 2.8% to $12.47 in pre-market trading.

Benzinga · May 12, 2022